Has Bradley Reames, MD received payments from drug or device companies?

Yes. Drug and device makers reported $52,578 in general payments to Bradley Reames, MD across 68 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Bradley Reames, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Bradley Reames, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Bradley Reames, MD

Surgical Oncology · Omaha, NENPI 1023246220

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (49.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 98.2% of it on its own, with 4 other manufacturers making up the rest.

$52,578in general payments, 2019–2025

Across 68 payments — averaging $773.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boston Scientific$52K
Dilon Technologies, Inc.$360
Intuitive Surgical$344
Advanced Accelerator Applications$121
AstraZeneca$116

What the payments were for

Consulting fees$26,12550%
Speaking & faculty fees$19,00036%
Travel & lodging$5,71311%
Food & beverage$1,7403%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boston Scientific	60	$51,638
Dilon Technologies, Inc.	2	$360
Intuitive Surgical	4	$344
Advanced Accelerator Applications	1	$121
AstraZeneca	1	$116

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few surgical oncology providers in Nebraskato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024

$89,263

Medicare patients

121

Services billed

349

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
CreonLipase/Protease/Amylase	16	$42,882
Pantoprazole Sodium	14	$184

Paid to pharmacies, not to this prescriber.

Other surgical oncology in Omaha

Jessica MaxwellOmaha$26K
George DittrickOmaha$9K
Quan LyOmaha$3K
Nicole DerosaOmaha$3K
Joshua MammenOmaha$2K
Juan SantamariaOmaha$823
James PadussisOmaha$788
Jessica ShankOmaha$56
Brian LoggieOmaha$18
Abbey FingeretOmaha$0

See the full list for Nebraska →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →